A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Aurora-A Expression Is Independently Associated with Chromosomal Instability in Colorectal Cancer

(2015) Yoshifumi Baba et al.   NEOPLASIA

The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents

(2011) Deborah R. Wysong et al.   CELL CYCLE

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

(2009) D. Hose et al.   BLOOD

Aurora kinase A is a target of Wnt/ -catenin involved in multiple myeloma disease progression

(2009) J. Dutta-Simmons et al.   BLOOD

Biologic sequelae of I B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

(2009) T. Hideshima et al.   BLOOD

In vitroanti-myeloma activity of the Aurora kinase inhibitor VE-465

(2009) Joseph M. Negri et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Genetic Variant of Aurora Kinase A Promotes Genomic Instability Leading to Highly Malignant Skin Tumors

(2009) E. C. Torchia et al.   CANCER RESEARCH

Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents

(2009) John R. Pollard et al.   JOURNAL OF MEDICINAL CHEMISTRY

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

(2009) X. Shang et al.   MOLECULAR CANCER THERAPEUTICS

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma

(2008) Robert P. Evans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells

(2008) Robert Evans et al.   LEUKEMIA & LYMPHOMA